Source: International Congress 2018 – Lung cancer: novel prognostic markers and scores
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
K. In (Seoul, Republic of Korea), S. Choi (Seoul, Republic of Korea), S. Lee (Seoul, Republic of Korea), S. Lee (Seoul, Republic of Korea). Clinical usefulness of natural killer cell activity in patients with non-small cell lung cancer. 2786

Member's Comments

No comment yet.

Related content which might interest you: Proliferative activity of non-small cell lung cancer after induction chemotherapy Source: Eur Respir J 2005; 26: Suppl. 49, 328s Year: 2005 Prognostic significance of tumour-infiltrating natural killer cells subset CD57 in patients with nonsmall cell lung cancer Source: Eur Respir J 2002; 20: Suppl. 38, 2s Year: 2002 Clinical implication of stem cell markers in N2 positive non-small cell lung cancer Source: Annual Congress 2012 - Prognosis of lung cancer Year: 2012 Clinical features of nonsmall cell lung cancer cases Source: Eur Respir J 2002; 20: Suppl. 38, 75s Year: 2002 Biological therapies in nonsmall cell lung cancer Source: Eur Respir J , 49 (3) 1601520; DOI: 10.1183/13993003.01520-2016 Year: 2017 Quantification of telomerase activity is important in predicting prognosis of patients with non-small cell lung cancer Source: Eur Respir J 2005; 26: Suppl. 49, 482s Year: 2005 Deguelin enhances chemosensitivity of non-small cell lung cancer cells Source: Eur Respir J 2006; 28: Suppl. 50, 336s Year: 2006 CHD4 is associated with poor prognosis of non-small cell lung cancer patients through promoting tumor cell proliferation Source: International Congress 2016 – Prognostic variables in lung cancer I Year: 2016 Soluble non-invasive markers in non-small cell lung cancer Source: Eur Respir J 2005; 26: Suppl. 49, 459s Year: 2005 Prognostic and potential therapeutic impact of prostate specific membrane antigen expression in non-small cell lung cancer Source: International Congress 2018 – Lung cancer: novel prognostic markers and scores Year: 2018 Prognostic value of neutrophil to lymphocyte ratio in patients with advanced non-small cell lung cancer Source: Virtual Congress 2021 – Therapy of lung cancer Year: 2021 Anticancer treatment for advanced non-small cell lung cancer Source: Breathe 2011; 8: 124-133 Year: 2011 Update on nonsmall cell lung cancer Source: Eur Respir Rev 2010 19: 173-185 Year: 2010 Ras peptide-specific vaccination in patients with non-small cell lung cancer (NSCLC) Source: Annual Congress 2006 - Lung cancer treatment Year: 2006 Effect of comorbidity on the prognosis of non-small cell lung cancer Source: Eur Respir J 2006; 28: Suppl. 50, 385s Year: 2006 Second line therapy for advanced non-small cell lung cancer Source: European Multidisciplinary Conference in Thoracic Oncology 2009 Year: 2009 Clinical significance and functional roles of FoxM1 in non-small cell lung cancer Source: Annual Congress 2012 - New biomarkers for lung cancer Year: 2012 Efficacy of local therapy for oligoprogressive disease after PD-1 blockade in advanced non-small cell lung cancer Source: Virtual Congress 2021 – COVID-19 and management of lung cancer Year: 2021 New treatment options for nonsmall cell lung cancer and small cell lung cancer Source: Annual Congress 2006 - PG12 - Small cell lung cancer management Year: 2006